| Dr Vincent Tam Nguyen, MD | |
|
17520 Old Jefferson Hwy, Ste B, Prairieville, LA 70769-3929 | |
| (225) 673-8983 | |
| (225) 677-8983 |
| Full Name | Dr Vincent Tam Nguyen |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 20 Years |
| Location | 17520 Old Jefferson Hwy, Prairieville, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053459644 | NPI | - | NPPES |
| 248568YRBU | Other | LA | MEDICARE PTAN |
| 1071005 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD200621 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baton Rouge General Medical Center | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baton Rouge General Physicians Inc | 5193623643 | 95 |
News Archive
A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.
Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.
› Verified 7 days ago
| Entity Name | Baton Rouge General Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992729560 PECOS PAC ID: 5193623643 Enrollment ID: O20080611000068 |
News Archive
A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.
Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.
› Verified 7 days ago
| Entity Name | Doctors After Hours Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114176971 PECOS PAC ID: 3072649615 Enrollment ID: O20100407000313 |
News Archive
A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.
Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.
› Verified 7 days ago
| Entity Name | Doctors After Hours Urgent Care & Walk In Clinic Clearview Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962710509 PECOS PAC ID: 9335336452 Enrollment ID: O20101215000030 |
News Archive
A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.
Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.
› Verified 7 days ago
| Entity Name | Doctors After Hours Urgent Care & Walk In Clinic - Lakeview L.l.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417245531 PECOS PAC ID: 2860667714 Enrollment ID: O20111206000045 |
News Archive
A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.
Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vincent Tam Nguyen, MD 8490 Picardy Ave, Bldg 200, Baton Rouge, LA 70809-3731 Ph: (225) 237-1754 | Dr Vincent Tam Nguyen, MD 17520 Old Jefferson Hwy, Ste B, Prairieville, LA 70769-3929 Ph: (225) 673-8983 |
News Archive
A new study published in the American Journal of Transplantation reveals that there is a significant risk of serious skin cancers, including cutaneous squamous cell carcinoma and melanoma, in heart transplant patients.
Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that it reached an agreement to sell its RapidTrace® solid phase extraction and TurboVap® evaporation product lines to Biotage AB for $16.5 million in cash.
Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens' entry into the point-of-care PT-INR testing market.
Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.
› Verified 7 days ago
Tina Trahan Wells, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 17520 Old Jefferson Hwy, Ste. B, Prairieville, LA 70769 Phone: 225-673-8983 Fax: 225-677-8983 | |
Dr. Robert Mark Sayes, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 17520 Old Jefferson Hwy, Ste B, Prairieville, LA 70769 Phone: 225-673-8983 Fax: 225-677-8983 | |
Angela D Kennerly, FNP-C Family Medicine Medicare: Medicare Enrolled Practice Location: 42079 Greenfield Xing, Prairieville, LA 70769 Phone: 225-278-9275 | |
Stephanie Coleman-lawrence, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 17520 Old Jefferson Hwy Ste B, Prairieville, LA 70769 Phone: 225-673-8983 Fax: 225-677-8983 | |
Jean Jacques Saunders, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 17609 Old Jefferson Hwy, Prairieville, LA 70769 Phone: 225-677-9595 Fax: 225-677-9695 | |
Mr. Jacob Sommers, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 36428 Manchac Trace Ave, Prairieville, LA 70769 Phone: 225-252-2411 |